![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANKMY2 |
Gene summary for ANKMY2 |
![]() |
Gene information | Species | Human | Gene symbol | ANKMY2 | Gene ID | 57037 |
Gene name | ankyrin repeat and MYND domain containing 2 | |
Gene Alias | ZMYND20 | |
Cytomap | 7p21.1 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024R9Z6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57037 | ANKMY2 | P79T-E | Human | Esophagus | ESCC | 1.34e-12 | 2.45e-01 | 0.1154 |
57037 | ANKMY2 | P80T-E | Human | Esophagus | ESCC | 2.10e-11 | 2.58e-01 | 0.155 |
57037 | ANKMY2 | P82T-E | Human | Esophagus | ESCC | 2.13e-13 | 4.57e-01 | 0.1072 |
57037 | ANKMY2 | P83T-E | Human | Esophagus | ESCC | 1.91e-10 | 2.26e-01 | 0.1738 |
57037 | ANKMY2 | P84T-E | Human | Esophagus | ESCC | 5.19e-04 | 2.67e-01 | 0.0933 |
57037 | ANKMY2 | P91T-E | Human | Esophagus | ESCC | 2.34e-02 | 2.36e-01 | 0.1828 |
57037 | ANKMY2 | P107T-E | Human | Esophagus | ESCC | 1.92e-06 | 1.49e-01 | 0.171 |
57037 | ANKMY2 | P127T-E | Human | Esophagus | ESCC | 1.86e-06 | 9.43e-02 | 0.0826 |
57037 | ANKMY2 | P128T-E | Human | Esophagus | ESCC | 1.48e-16 | 5.15e-01 | 0.1241 |
57037 | ANKMY2 | P130T-E | Human | Esophagus | ESCC | 5.23e-20 | 2.81e-01 | 0.1676 |
Page: 1 2 3 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANKMY2 | SNV | Missense_Mutation | c.716N>A | p.Gly239Glu | p.G239E | Q8IV38 | protein_coding | tolerated(0.3) | benign(0.079) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ANKMY2 | SNV | Missense_Mutation | c.660N>A | p.Met220Ile | p.M220I | Q8IV38 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ANKMY2 | deletion | Frame_Shift_Del | novel | c.473delN | p.Pro158GlnfsTer22 | p.P158Qfs*22 | Q8IV38 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
ANKMY2 | SNV | Missense_Mutation | rs768714189 | c.907N>A | p.Val303Ile | p.V303I | Q8IV38 | protein_coding | tolerated(0.27) | benign(0.015) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
ANKMY2 | SNV | Missense_Mutation | c.1078N>A | p.Leu360Met | p.L360M | Q8IV38 | protein_coding | deleterious(0.01) | possibly_damaging(0.888) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ANKMY2 | SNV | Missense_Mutation | c.1248G>T | p.Lys416Asn | p.K416N | Q8IV38 | protein_coding | tolerated_low_confidence(0.19) | benign(0.003) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ANKMY2 | SNV | Missense_Mutation | c.820N>G | p.Phe274Val | p.F274V | Q8IV38 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
ANKMY2 | SNV | Missense_Mutation | novel | c.901N>A | p.Phe301Ile | p.F301I | Q8IV38 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANKMY2 | SNV | Missense_Mutation | rs771078807 | c.395N>C | p.Ile132Thr | p.I132T | Q8IV38 | protein_coding | deleterious(0) | possibly_damaging(0.886) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
ANKMY2 | SNV | Missense_Mutation | novel | c.370G>A | p.Gly124Ser | p.G124S | Q8IV38 | protein_coding | deleterious(0.05) | probably_damaging(0.932) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |